Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPrudential Regulatory News (PRU)

Share Price Information for Prudential (PRU)

Share Price is delayed by 15 minutes
Get Live Data
950.60    -24.20 (-2.48%)
Bid:
955.20
Ask:
955.60
Spread: 0.40 (0.042%)
Market Cap: £23.79b
PRU Live PriceLast checked at - London Stock Exchange

Intraday Prudential Share Chart

Board changes

1 Jul 2025 11:39

RNS Number : 2337P
Prudential PLC
01 July 2025
 

Prudential plc Board changes

 

Prudential plc ("Prudential", the "Company") announces the following changes to its Board of Directors:

Appointment of Dr Guido Fürer as a Non-executive Director

Dr Guido Fürer has been appointed to the Board with immediate effect. He will also be a member of the Audit and Risk Committees.

Dr Fürer has extensive international experience of the insurance and asset management industries. His 25-year career at Swiss Re Group included 11 years as Group Chief Investment Officer and member of the Global Executive Committee, heading up the Global Asset Management division, as well as a term as Country President, Switzerland, and Chair of the Group Strategic Council. Prior to joining Swiss Re, Dr Fürer held leading positions at Swiss Bank Corp /O'Connor and Associates in options trading and capital markets.

Between 2018 and 2022 Dr Fürer was a non-executive director, and chaired the Group Risk Committee, of FWD Group, gaining insight into various of Prudential's key markets. He is currently a non-executive director of Baloise Group and chair of its Risk & Investment Committee.

Retirement of Amy Yip

Following the completion of six years in office, Amy Yip will retire from the Board with effect from 31 October 2025. Ms Yip joined the Board in September 2019. She has been a member of the Audit Committee since March 2021 and prior to that was a member of the Remuneration Committee.

Shriti Vadera, Chair of Prudential, said: "Guido brings a wealth of knowledge and expertise, including in respect of asset management, insurance and asset-liability management, from both a distinguished executive career and from his global board experience. I am delighted to welcome him on to the Board".

"At the same time, we will be sorry to lose Amy later in the year after six years on the Board. On behalf of the Board, I would like to take the opportunity to thank Amy for her valuable contribution in helping the Board to guide and oversee the Group through a period of significant change."

Contact

Media

Investors/analysts

Simon Kutner

+44 7581 023260

Patrick Bowes

+852 2918 5468

Sonia Tsang

+852 5580 7525

William Elderkin

+44 20 3977 9215

 

 

Ming Hau

+44 20 3977 9293

 

 

Bosco Cheung

+852 2918 5499

 

 

Tianjiao Yu

+852 2918 5487

 

Notes to Editors

About Guido Fürer

Dr Fürer has over three decades of international experience across financial services. He began his career with Swiss Bank Corporation/O'Connor & Associates in options trading and in its Capital Markets division in Chicago, New York, London and Zurich. In 1997 he joined Swiss Re, where he held various positions before being appointed Group Chief Investment Officer and member of the Group Executive Committee in 2012, heading up Group Asset Management until his retirement in March 2023.

Between 2019 and 2023, Dr Fürer served as Country President, Swiss Re Switzerland, and held the roles of Chair of Swiss Re's Strategic Council, Zurich Pension Fund, and Trustee of the Swiss Re Foundation.

During his time at Swiss Re Dr Fürer served on the boards of a number of subsidiary entities and, from 2018 to 2022, as a non-executive director of pan-Asian insurer FWD Group, where he chaired the Group Risk Committee. In addition, he played a significant role in the establishment of the UN-enabled Net-Zero Asset Owner Alliance.

Following his retirement, Dr Fürer became a member of the board of insurance and banking group Baloise Holding AG in April 2024, becoming Chair of the Risk & Investment Committee in April 2025.

Dr Fürer has a master's degree in Economics and a doctorate in Financial Risk Management from the University of Zurich, where he is now Chair of the Advisory Board of the Department of Finance. 

Age

61

Shareholding

Dr Fürer does not hold any interest in shares of Prudential plc.

Length of service

Non-executive Directors are usually appointed for an initial three-year term. They are typically expected to serve for two three-year terms, although the Board may invite them to serve for an additional period.

Remuneration

Non-executive Directors are not eligible to participate in annual bonus plans, long-term incentive plans or pension arrangements. Their fees are determined by the Board and reflect their individual responsibilities, including committee membership as appropriate.

On appointment, Dr Fürer will receive the standard annual Non-executive Director fee of $125,000, in addition to which he will receive an additional annual fee of $39,000 for his membership of the Audit Committee and an additional annual fee of $39,000 for his membership of the Risk Committee.

Regulatory Disclosures

Dr Fürer is considered independent for the purposes of the UK Corporate Governance Code and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (Hong Kong Listing Rules).

Dr Fürer has confirmed (a)his independence as regards each of the factors referred to in Hong Kong Listing Rule 3.13; (b) he does not have any past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person of the Company (as defined by the Hong Kong Listing Rules); and (c) there are no other factors that may affect his independence at the time of his appointment.

Dr Fürer has also joined the Board of Prudential Corporation Asia Limited, a wholly owned subsidiary of Prudential, with immediate effect. Dr Fürer has confirmed to the Company that all of the biographical and other relevant information required by UK Listing Rules 6.4.8R - 6.4.10G and / or Hong Kong Listing Rule 13.51(2) has been disclosed in full and that those details are true, accurate and complete. The Company is not aware of any other matters in relation to his appointment or otherwise that need to be brought to the attention of Prudential's shareholders.

Ms Yip has confirmed to the Company that she has no disagreement with the Board and that there are no matters that need to be brought to the attention of Prudential's shareholders in respect of her resignation.

About Prudential plc

Prudential provides life and health insurance and asset management in 24 markets across Asia and Africa. Prudential's mission is to be the most trusted partner and protector for this generation and generations to come, by providing simple and accessible financial and health solutions. The business has dual primary listings on the Stock Exchange of Hong Kong (2378) and the London Stock Exchange (PRU). It also has a secondary listing on the Singapore Stock Exchange (K6S) and a listing on the New York Stock Exchange (PUK) in the form of American Depositary Receipts. It is a constituent of the Hang Seng Composite Index and is also included for trading in the Shenzhen-Hong Kong Stock Connect programme and the Shanghai-Hong Kong Stock Connect programme.

Prudential is not affiliated in any manner with Prudential Financial, Inc. a company whose principal place of business is in the United States of America, nor with The Prudential Assurance Company Limited, a subsidiary of M&G plc, a company incorporated in the United Kingdom.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFZGGNGMKGKZM
Date   Source Headline
12th Apr 20213:26 pmRNSNotice of Annual General Meeting 2021
12th Apr 20219:30 amRNSDirector/PDMR Shareholding
1st Apr 20219:10 amRNSTotal Voting Rights
26th Mar 20219:17 amRNSDirector/PDMR Shareholding
23rd Mar 20217:00 amRNSFiling of Form 10 Registration Statement
19th Mar 20219:00 amRNSBlock Listing Application
18th Mar 20218:30 amRNSPrudential appoints new Non-Executive Director
16th Mar 202112:32 pmRNSPublication of Supplementary Prospectus
15th Mar 202111:21 amRNSAnnual Report and Accounts 2020 and Form 20-F
11th Mar 20219:30 amRNSDirector/PDMR Shareholding
9th Mar 20219:30 amRNSDirector/PDMR Shareholding
3rd Mar 20218:45 amRNS2020 Second Interim Dividend
3rd Mar 20218:39 amRNSPrudential Vietnam expands partnership with MSB
3rd Mar 20218:30 amRNSPrudential plc – FY20 Results – Risk Factors
3rd Mar 20218:30 amRNSPrudential plc – FY20 Results – EEV
3rd Mar 20218:30 amRNSPrudential plc – FY20 Results – IFRS
3rd Mar 20218:30 amRNSPrudential plc – FY20 Results – Business Review
1st Mar 20219:30 amRNSTotal Voting Rights
11th Feb 20219:30 amRNSDirector/PDMR Shareholding
11th Feb 20217:00 amRNSPrudential plc - Update on leadership of Jackson
10th Feb 202110:00 amRNSDirector/PDMR Shareholding
4th Feb 20218:30 amRNSBoard and Committee Changes
1st Feb 202110:00 amRNSTotal Voting Rights
28th Jan 20218:34 amRNSPrudential plc - Update on separation of Jackson
12th Jan 202112:00 pmRNSDirector/PDMR Shareholding
11th Jan 20212:00 pmRNSDirector/PDMR Shareholding
4th Jan 202112:00 pmRNSTotal Voting Rights
11th Dec 202010:00 amRNSDirector/PDMR Shareholding
9th Dec 202011:30 amRNSDirector/PDMR Shareholding
3rd Dec 20201:00 pmRNSChair succession effective 1 January 2021
1st Dec 202010:00 amRNSTotal Voting Rights
30th Nov 20204:41 pmRNSSecond Price Monitoring Extn
30th Nov 20204:37 pmRNSPrice Monitoring Extension
24th Nov 20209:00 amRNSSix monthly blocklisting
12th Nov 20209:00 amRNSBlocklisting
11th Nov 202010:00 amRNSDirector/PDMR Shareholding
10th Nov 202010:45 amRNSDirector/PDMR Shareholding
10th Nov 20209:00 amRNSDirector/PDMR Shareholding
2nd Nov 202010:00 amRNSTotal Voting Rights
30th Oct 20209:00 amRNSDirector/PDMR Shareholding
13th Oct 202010:00 amRNSDirector/PDMR Shareholding
9th Oct 20201:00 pmRNSDirector/PDMR Shareholding
2nd Oct 202012:30 pmRNSDirector/PDMR Shareholding
1st Oct 202010:00 amRNSDirector/PDMR Shareholding
1st Oct 202010:00 amRNSTotal Voting Rights
28th Sep 202010:00 amRNSDirector/PDMR Shareholding
23rd Sep 202010:00 amRNSDirector/PDMR Shareholding
23rd Sep 20207:02 amRNSPrice Monitoring Extension
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
17th Sep 202010:00 amRNSDividend conversion rates achieved

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.